ClinicalTrials.gg
RecruitingNCT06824376HUA,SUA,MAUpdated Mar 30, 2025

Manual Acupuncture (MA) for Asymptomatic Hyperuricemia (HUA)

An interventional study of Manual acupuncture and Sham acupuncture in Asymptomatic Hyperuricemia, sponsored by Shenghao Tu. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by Shenghao Tu · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Assess the effectiveness of manual acupuncture in modulating serum uric acid levels among patients diagnosed with asymptomatic hyperuricemia.

Read the detailed description

This is a multicenter randomized, single-blind, sham-controlled trial. A total of 260 eligible patients with asymptomatic hyperuricemia will be randomly assigned in a 1:1 ratio to manual acupuncture group or sham acupuncture group.

02

Conditions studied

  • Asymptomatic Hyperuricemia

Browse trials for

Keywords

  • MA
  • HUA
  • SUA
  • deqi
03

In context

Hyperuricemia

240 studies on the registry are indexed under Hyperuricemia; 44 are open to participants now.

This study's planned enrollment of 260 is above the median of 68 across 193 interventional studies indexed under Hyperuricemia.

Browse Hyperuricemia studies →

Lead sponsor

This is the only study on the registry with Shenghao Tu as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • With serum uric acid (SUA) level >7 mg/dL after 1 month of a low-purine diet.
  • No history of gouty arthritis.
  • Has not received uric acid-lowering drug treatment or stopped uric acid- lowering drug treatment ≥ 12 weeks.
  • 18.5kg/m2 ≤ (BMI) ≤ 30.0 kg/m2.
  • Can write .

Exclusion criteria

Exclusion Criteria:

  • Patients with poorly controlled hypertension: systolic blood pressure (SBP) ≥ 160mmHg, diastolic blood pressure (DBP) ≥ 100 mmHg.
  • Patients with poorly controlled diabetes ( ≥ 8.4%).
  • Patients with severe liver and kidney damage: chronic kidney disease (CKD) ≥ stage 2 or a serum creatinine, urea, alanine, or level more than twice of the upper limit.
  • Patients with blood system diseases, such as acute and chronic leukemia, polycythemia, multiple myeloma, hemolytic anemia, lymphoma, or undergoing chemotherapy for multiple solid tumors.
  • Patients with stroke, coronary heart disease, or severe neuropsychological diseases.
  • Patients who are pregnant.
  • Illiterate or unwilling to accept acupuncture treatment.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
260 participants (estimated)

Study arms

  • Experimental
    Manual acupuncture group

    Acupuncturists will apply 20 sessions of 30-mintute manual acupuncture at 10 obligatory acupoints, over 8 weeks of treatment period.

    Device: Manual acupuncture

  • Sham comparator
    Sham acupuncture group

    20 sessions of non-penetrating sham acupuncture will be performed at non-acupuncture points, which are located on the back and with different segments from the kidney organ area,over 8 weeks of treatment period.

    Device: Sham acupuncture

Interventions

  • DeviceManual acupuncture

    After sterilisation, the sharp needles will be inserted into the deep tissue layers of acupoints. Acupuncturists will tried to elicit acupuncture de-qi sensation by the manual manipulation of needles. Within a 30-minute period, manual manipulation for each acupoint will last at least 10 seconds and wil repeated four times with intervals of 10-minute.

  • DeviceSham acupuncture

    After sterilisation, Streitberger placebo needles with blunt tip will be used. It can be fixed on the surface of the sham points without piercing the skin. Within a 30-minute period, each point will undergo a simulated twisting motion of the needle for at least 10 seconds, and this will be repeated four times at 10-minute intervals.

06

What researchers measure

Primary outcomes

  1. Serum uric acid (SUA)

    Changes in the SUA level after 8 weeks of treatment.

    Time frame: Baseline and 8 weeks after randomization.

Secondary outcomes

  1. Proportion of participants with SUA ≤ 6.0 mg/dL

    The proportion of participants with SUA ≤ 6.0 mg/dL after treatment.

    Time frame: 4 weeks after randomization, 8 weeks after randomization, 12 weeks after randomization and 16 weeks after randomization.

  2. Proportion of participants with SUA ≤ 7.0 mg/dL.

    The proportion of participants with SUA ≤ 7.0 mg/dL after treatment.

    Time frame: 4 weeks after randomization, 8 weeks after randomization, 12 weeks after randomization and 16 weeks after randomization.

  3. Dynamic changes in the SUA level after treatment.

    Time frame: Baseline, 4 weeks after randomization, 12 weeks after randomization and 16 weeks after randomization.

  4. The proportion of participants with gout attacks

    The proportion of participants with gout attacks after randomization

    Time frame: 4 weeks after randomization, 8 weeks after randomization, 12 weeks after randomization and 16 weeks after randomization.

Other outcomes

  1. Body weight

    Changes in the body weight after treatment.

    Time frame: baseline, 4 weeks after randomization, 8 weeks after randomization, 12 weeks after randomization and 16 weeks after randomization.

  2. Abdominal circumference

    Changes in abdominal circumference after treatment.

    Time frame: baseline, 4 weeks after randomization, 8 weeks after randomization, 12 weeks after randomization and 16 weeks after randomization.

  3. NEO Personality Inventory-Short Form (NEO-FFI)

    NEO Personality Inventory-Short Form (NEO-FFI)

    Time frame: baseline, 4 weeks after randomization, 8 weeks after randomization, 12 weeks after randomization and 16 weeks after randomization.

  4. Traditional Chinese medicine (TCM) constitution

    Changes in the Traditional Chinese medicine (TCM) constitution after treatment

    Time frame: baseline, 4 weeks after randomization, 8 weeks after randomization, 12 weeks after randomization and 16 weeks after randomization.

  5. Pittsburgh Sleep Quality Index (PSQI)

    Changes in the PSQI after 4 weeks of treatment.

    Time frame: baseline, 4 weeks after randomization, 8 weeks after randomization, 12 weeks after randomization and 16 weeks after randomization.

  6. Beck Depression Inventory II (BDI- II)

    Changes in the BDI- II after treatment.

    Time frame: baseline, 4 weeks after randomization, 8 weeks after randomization, 12 weeks after randomization and 16 weeks after randomization.

  7. Beck Anxiety Inventory (BAI)

    Changes in the BAI after treatment

    Time frame: baseline, 4 weeks after randomization, 8 weeks after randomization, 12 weeks after randomization and 16 weeks after randomization.

  8. Adverse events (AEs)

    AEs in which a causal relationship to the manual acupuncture or sham acupuncture cannot be ruled out will be considered an adverse reactions from the acupuncture. AEs related to acupuncture may include abnormal pain, bleeding, congestion, broken needles, bent needles, and dizziness.

    Time frame: From the beginning of acupuncture , up to 24 hours after acupuncture.

  9. The intensity of acupuncture de qi sensation.

    The Massachusetts General Hospital (MGH) Acupuncture Sensation Scale (MASS) after each manual or sham acupuncture treatment

    Time frame: Ten minutes after each manual or sham acupuncture treatment.

07

Study locations

1 of 1 sites recruiting
  • Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430030, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — IPD after de-identification can be shared on individual request to the principal investigator at shtu@tjh.tjmu.edu.cn

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: IPD and supporting information will be available after the publication of the primary outcomes.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Oct 2026, 19 months after the start.

Of 26 interventional studies with no phase under Hyperuricemia, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 34. This study's planned 19 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2025
First posted
Feb 13, 2025
StartActual
Mar 25, 2025
Primary completionEst.
Oct 2026
CompletionEst.
Dec 2026
Last update
Mar 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06824376
Lead sponsor
Shenghao Tu
Collaborators
Wuhan Union Hospital, China, Xianning Hospital of Traditional Chinese Medicine, China, Beijing Hospital of Traditional Chinese Medicine, Qianjiang Central Hospital, China, Hainan General Hospital, Yichang Central People's Hospital, Wuhan No.1 Hospital, The Second Hospital of Huangshi, Puyang Hospital of Traditional Chinese Medicine
Responsible party
Shenghao Tu (Professor, Tongji Hospital) — Sponsor-investigator
First posted
Feb 13, 2025
Start date
Mar 25, 2025
Primary completion
Oct 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Mar 30, 2025

Study contacts

Shenghao Tu, PhD
Contact
shtu@tjh.tjmu.edu.cn
86-13971535353
Lingling Yu, PhD
Contact
527679774@qq.com
86-13545862185
Shenghao Tu, Ph.D
principal investigator · Tongji Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion